Pathos AI Overview

  • Status
  • Private

  • Employees
  • 85

Employees

  • Latest Deal Type
  • Series E

  • Latest Deal Amount
  • $237M

  • Investors
  • 6

Pathos AI General Information

Description

Developer of a drug discovery platform designed to reduce the duration of the medication development process. The company's self-learning platform uses big data, technology, and artificial intelligence to identify targets, validate them, and establish their clinical efficacy, enabling drug developers to explore novel concepts and advance breakthrough therapies for cancer and other diseases.

Contact Information

Website
www.pathos.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • New York, NY
  • United States
Primary Industry
Discovery Tools (Healthcare)
Other Industries
Drug Discovery
Corporate Office
  • New York, NY
  • United States

Pathos AI Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pathos AI Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series E) 23-Oct-2026 $237M Completed Clinical Trials - Phase 2
4. Later Stage VC (Series D) 15-May-2025 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 29-Oct-2024 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series B) 02-Mar-2023 $30M $40M Completed Clinical Trials - Phase 1
1. Early Stage VC (Series A) 17-Jul-2021 $10M $10M Completed Startup
To view Pathos AI’s complete valuation and funding history, request access »

Pathos AI Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series E
Series D
Series C
Series B 11,076,813 $0.000100 5% $2.92 $2.92 1x $2.92 3.77%
Series A 10,000,000 $0.000100 5% $1 $1 1x $1 3.41%
To view Pathos AI’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Pathos AI Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a drug discovery platform designed to reduce the duration of the medication development process. The compan
Discovery Tools (Healthcare)
New York, NY
85 As of 2025

Boulder, CO
 

Nottingham, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pathos AI Competitors (2)

One of Pathos AI’s 2 competitors is Enveda, a Venture Capital-Backed company based in Boulder, CO.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Enveda Venture Capital-Backed Boulder, CO
Sygnature Discovery Private Equity-Backed Nottingham, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

Pathos AI Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pathos AI Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bristol-Myers Squibb Corporation Minority
New Enterprise Associates Venture Capital Minority
Revolution (Washington DC) Venture Capital Minority
Builders VC Venture Capital Minority
Angel (individual) Minority
You’re viewing 5 of 6 investors. Get the full list »

Pathos AI Investments & Acquisitions (4)

Pathos AI’s most recent deal was a Merger/Acquisition with DeuterOncology. The deal was made on 06-May-2026.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
DeuterOncology 06-May-2026 Merger/Acquisition Drug Discovery
Envisso 16-Mar-2026 Seed Round Financial Software
Rain Oncology 26-Jan-2024 Merger/Acquisition Drug Delivery
Known Medicine 23-May-2023 Merger/Acquisition Biotechnology
To view Pathos AI’s complete investments and acquisitions history, request access »

Pathos AI Affiliates

Subsidiaries (3)

Name Industry Location Year Founded
DeuterOncology Liege, Belgium 2020
Known Medicine Salt Lake City, UT 2020
Rain Oncology Newark, CA 2017

Pathos AI FAQs

  • Where is Pathos AI headquartered?

    Pathos AI is headquartered in New York, NY.

  • What is the size of Pathos AI?

    Pathos AI has 85 total employees.

  • What industry is Pathos AI in?

    Pathos AI’s primary industry is Discovery Tools (Healthcare).

  • Is Pathos AI a private or public company?

    Pathos AI is a Private company.

  • What is the current valuation of Pathos AI?

    The current valuation of Pathos AI is .

  • What is Pathos AI’s current revenue?

    The current revenue for Pathos AI is .

  • How much funding has Pathos AI raised over time?

    Pathos AI has raised $704M.

  • Who are Pathos AI’s investors?

    Bristol-Myers Squibb, New Enterprise Associates, Revolution (Washington DC), Builders VC, and are 5 of 6 investors who have invested in Pathos AI.

  • Who are Pathos AI’s competitors?

    Enveda and Sygnature Discovery are competitors of Pathos AI.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process